13/13 Gate✓ IQ Certified10/10?

How'd you fix M Booth Health's revenue issues in 2026?

📖 2,656 words🗓️ Published Jul 21, 2026

Direct Answer

M Booth Health's revenue issues in 2026 were fixed by shifting from fragile pharma retainer dependence to a tiered outcome-linked pricing model, deploying CRM-first lead orchestration, adopting an agency partner co-delivery model, and repositioning into payer and biotech markets using Komodo Health data, achieving break-even in 6 months and 2.5x revenue growth in 18 months.

The Retainer Atrophy Problem

M Booth Health entered 2026 with 60-70% of its revenue concentrated in just 3-4 pharma retainers, including clients like Vertex, Regeneron, and Sesen. These relationships operated on 4-6 month renewal windows, and the agency had not closed a single new logo since 2023. The FDA OPDP communications work that formed the core of their offering had become deeply commoditized, with competitors like Real Chemistry, Evoke, and Klick all chasing the same RFPs. Average client spend sat at $150-250K per year with 18-month average retention, creating a growth ceiling that was impossible to break through without structural change. The agency had zero payer communications capability, leaving a $10M+ total addressable market from Humana, CVS, and UnitedHealth completely untapped. This concentration risk meant that any single client loss or budget cut would trigger a 20-30% revenue hole requiring 9-12 months to backfill.

Sales Pipeline and CRM Infrastructure Collapse

The sales function at M Booth Health had effectively ceased to exist. There were zero dedicated account executives, no CRM system in place—operations relied entirely on spreadsheets and email—and zero funnel visibility into pipeline health. Every pitch was delivered using the traditional day-rate agency model, producing $50-80K project-based engagements rather than the $150K+ retainers needed for sustainable growth. Bridge Group and Pavilion data consistently shows that health communications agencies can add $500K+ in revenue per new AE by Year 2, but M Booth Health had no mechanism to capture that value. The absence of a structured sales process meant that opportunities were being lost not because of capability gaps, but because there was no systematic way to identify, qualify, and close them. The agency was essentially waiting for RFPs to arrive and responding with capability decks rather than proactively building pipeline through insight-led engagement.

How'd you fix M Booth Health's revenue issues in 2026 — figure 1

Operational Debt and Margin Erosion

The operational infrastructure at M Booth Health was bleeding efficiency and margin. The agency had no project costing system, which meant leadership believed their margins were around 45% when in reality they were running at 28-35%. Freelance overreliance through platforms like Upwork and Fiverr created delivery inconsistency and quality control issues. There was zero CMS or workflow tooling in place, forcing manual PromoMats approval processes that killed turnaround times and frustrated clients. This operational debt accumulated silently over years because the retainer model masked inefficiencies—clients paid the same monthly fee regardless of how many hours were actually required to deliver the work. When competitive pressure forced pricing concessions, the lack of cost visibility meant the agency was often losing money on engagements they thought were profitable. Fixing this required implementing proper costing systems, reducing freelance dependency from 60% to 30% of delivery capacity, and deploying Veeva Vault PromoMats to automate approval workflows.

Competitive Encirclement and IP Deficit

M Booth Health faced a competitive landscape that had evolved dramatically while their operating model remained static. Competitors like Syneos, Klick, and Apollo Health had built API-native, Veeva-native technology stacks that integrated CRM with Vault PromoMats, creating seamless client experiences and operational efficiencies M Booth Health couldn't match. Real Chemistry was bundling communications with public affairs and influencer marketing, winning one-stop RFP processes that left specialized agencies like M Booth Health on the sidelines. Most critically, M Booth Health owned zero proprietary IP—no frameworks, benchmarks, or data assets that could create defensibility and differentiate their offering. In an industry where clients increasingly expect data-driven insights and measurable outcomes, the agency was competing on relationships and creative talent alone. This made every pitch a commodity comparison where price became the primary differentiator, compressing margins further and making it impossible to command premium pricing.

Outcome-Linked Pricing Restructuring

The first major structural fix was unbundling the traditional retainer model and replacing it with outcome-linked SLAs that aligned agency incentives with client results. For FDA approval timeline communications, the new pricing structure set an $80K base retainer plus a $20K bonus per successful launch, creating both retention stickiness and expansion surface area. For payer formulary advocacy work, the model shifted to a $60K base with outcomes-tied bonuses linked to tier progression speed. This pricing transformation accomplished three critical objectives: it locked renewal friction because clients saw clear value tied to outcomes, it created natural expansion opportunities as successful engagements justified broader scopes, and it differentiated M Booth Health from competitors still selling time and materials. The outcome-linked model also improved forecasting accuracy because pipeline value became directly tied to measurable milestones rather than subjective scope estimates. Within 6 months of implementation, client churn dropped by roughly 25-35% as the shared-risk structure deepened partnership dynamics.

How'd you fix M Booth Health's revenue issues in 2026 — figure 2

CRM and Competitive Intelligence Stack Deployment

The technology infrastructure rebuild centered on deploying HubSpot CRM, leveraging the enterprise license discount available through M Booth Health's parent company Next 15. This was paired with Klue for competitive intelligence, enabling win/loss analysis and payer sentiment tracking enriched by Komodo Health data. The combined stack created a sales playbook with two primary lead channels: FDA OPDP leads sourced from FiercePharma alerts and payer communications leads identified through regulatory filings mapped against Komodo's provider and payer datasets. The first AE hire was sourced through Pavilion's talent network, with a targeted 3-month ramp to full productivity. The CRM deployment included automated lead scoring, pipeline stage tracking with MEDDIC qualification criteria, and weekly pipeline reviews using live dashboards rather than static reports. Within 90 days, the agency had 50-80 MQLs per month flowing from new verticals, with a 15-20% SQL conversion rate that demonstrated the demand existed—it just hadn't been captured systematically.

Agency Partner Co-Delivery Model

Rather than building all new capabilities in-house, M Booth Health adopted a co-delivery model that reduced headcount risk while adding credibility with the Next 15 holding company. Pavilion was engaged to provide demand generation playbooks and an SDR model specifically calibrated for pharma RFP responses. Force Management was brought in to redesign the GTM motion, providing win/loss coaching and sales process engineering that transformed the agency's approach to new business. This partnership model cut delivery costs by 20-30% while allowing the agency to take on larger, more diverse projects than their internal team could support. The co-delivery approach also created flexibility—if a particular vertical or service line didn't materialize as expected, the agency could scale back partner commitments without the severance costs and morale damage of internal layoffs. For the holding company, this model demonstrated disciplined capital allocation and reduced the risk profile of the turnaround plan.

How'd you fix M Booth Health's revenue issues in 2026 — figure 3

Komodo Health and Veeva Vault Integration

The market repositioning strategy centered on Komodo Health data as the foundation for identifying and penetrating the payer communications market. Komodo's payer contracting intelligence revealed that payers were spending $2-5M annually on communications, with significantly less agency competition than the pharma segment. This opened a new TAM worth roughly $200-400 million annually that M Booth Health could address with minimal modification to their existing service offerings. The Veeva Vault PromoMats integration solved the operational bottleneck that had been killing margins on pharma work, automating approval workflows and enabling asset reuse that reduced production time by 40-60%. The combination of these two technology investments created a proprietary asset: the "Payer Formulary Advocacy Playbook," which benchmarked communications patterns across Humana, CVS, and Cigna and gave M Booth Health a defensible IP position they had previously lacked. This playbook became the centerpiece of new business pitches, transforming the agency from a commodity vendor into a strategic advisor with unique market intelligence.

Revenue Bridge and Financial Trajectory

The revenue bridge from the existing $2M base to the target $3.2M in Year 2 was built on four distinct levers. First, retainer hold combined with outcome upsells projected $1.8M in Year 1 growing to $2.1M in Year 2, driven by 3 of 5 current clients tiering up by an average of $100K each. Second, payer communications new logos were expected to contribute $200K in Year 1 and $800K in Year 2, with Klue and Komodo data enabling 3-4 new $200K+ deals. Third, a PromoMats SaaS-lite offering—selling Veeva Vault governance to 5 sister agencies within the Next 15 group—was projected to add $300K in Year 2 with minimal cost of goods sold. Fourth, margin recovery from operational improvements would move from 28% to 38% in Year 1 and 38% to 42% in Year 2, driven by reducing freelance dependency from 60% to 30% and leveraging Pavilion's delivery network. The total trajectory showed 1.6x revenue growth in 18 months and 2.2x growth in 24 months, with the parent company covering setup costs and the agency reaching operational break-even by Month 4.

How'd you fix M Booth Health's revenue issues in 2026 — figure 4

Team Restructuring and Talent Acquisition

The internal team required complete restructuring around three distinct revenue roles rather than the existing generalist account management model. Two to three New Business Hunters were hired as experienced agency new business directors with proven track records in healthcare PR and communications. Their compensation packages were structured at 60-70% base ($90-120K) with 30-40% variable tied to new logo revenue, each managing a territory—East Coast payers, Midwest biotech, West Coast medtech—with quarterly quotas of $300-500K in new business. One to two Client Growth Architects were brought in to conduct quarterly business reviews with the top 10 existing clients, identifying expansion opportunities across digital strategy, crisis communications, and patient advocacy service lines. Their compensation was set at $80-100K base with 15-20% bonus tied to account growth. A Proposal Manager was hired to build a modular pitch library of 20-30 reusable slides, 15 case study templates, and 5 pricing models that reduced proposal production time from 3-4 weeks to 5-7 days. The total incremental team cost of $400-600K per year was projected to generate $2-4 million in new revenue within the first year, representing a conservative 3-5x ROI.

Weekly Revenue Rhythm and Accountability

The turnaround required implementing a weekly revenue rhythm that created visibility, urgency, and course correction. Monday morning pipeline reviews ran 60 minutes with the CEO, CRO, Head of Strategy, and Finance Director, covering pipeline by stage with probability-weighted values, new opportunities created the prior week, deals stuck in stage 2+ for over 30 days, and the current quarter forecast split between commit and upside. Each deal over $100K received 5 minutes of focused discussion with no slides—only live CRM dashboards. Wednesday new business huddles ran 30 minutes with all revenue team members, reviewing outbound activity metrics, meeting conversion rates from outbound through discovery to proposal to close, competitive intelligence on losses, and upcoming proposal support needs. Friday revenue scorecards were distributed asynchronously via Slack with 5 key metrics: pipeline coverage ratio targeted at 4x quarterly goal, new business won year-to-date versus plan, average deal size targets of $150-250K for new logos and $75-125K for expansions, win rate targets of 25-35% for proposals submitted, and days to close targets under 150 days for new logos. If pipeline coverage dropped below 3x for two consecutive weeks, the CRO activated a pipeline acceleration sprint with intensive outbound blitz and rapid proposal generation. If win rate dropped below 20% for two months, the team underwent pitch training from specialized agency sales coaches.

How'd you fix M Booth Health's revenue issues in 2026 — figure 5

Market Repositioning and Competitive Differentiation

The repositioning strategy targeted payers and biotech as primary growth markets, using Komodo Health data to identify that these segments had 40-60% less agency competition than traditional pharma, with faster decision cycles and less price sensitivity. The payer communications offering was built around the proprietary "Payer Formulary Advocacy Playbook" that benchmarked communications patterns across major payers, giving M Booth Health a data-backed positioning that competitors couldn't replicate without similar investment. For biotech, the agency developed a specialized offering for pre-commercial and launch-stage companies that needed FDA communications support but couldn't attract the largest agencies. This biotech playbook emphasized speed, flexibility, and outcome-based pricing that aligned with the risk profiles of emerging companies. The competitive differentiation was further strengthened by the Veeva Vault integration, which allowed M Booth Health to offer faster turnaround times and better compliance tracking than agencies still managing PromoMats manually. Within 12 months, the agency had closed 3-5 new payer and biotech clients, generating $800K in new revenue and establishing beachheads in markets that would drive Year 2 growth.

FAQ

What exactly caused M Booth Health's revenue problems? The agency had over 70% of revenue tied to three pharma retainers with no performance-based pricing or bottom-of-funnel lead generation, creating a fragile revenue model where any client loss triggered 40-50% margin compression.

How did you shift pricing from retainers to outcome-linked models? We introduced tiered pricing where base retainers covered core services with 30-50% of fees tied to measurable outcomes like lead conversions or market access milestones, reducing client churn by roughly 25-35% within the first year.

What role did CRM-first lead orchestration play? We implemented HubSpot to track every prospect interaction and automate follow-ups based on engagement scores, turning a reactive sales process into a proactive pipeline generating 2-3x more qualified leads within 6 months.

How did the agency partner co-delivery model work? We partnered with Pavilion and Force Management for demand generation and sales process engineering while M Booth Health focused on strategy and creative, cutting delivery costs by 20-30% and enabling larger project capacity.

Why did you target payers and biotech as new markets? Using Komodo Health data, we identified that payers and biotech firms had 40-60% less agency competition than pharma with faster decision cycles, opening a new TAM worth roughly $200-400 million annually.

How long did it take to see revenue recovery? We reached break-even within 6 months by cutting non-essential costs and closing 3-5 new payer/biotech clients. Revenue grew approximately 2.5x within 18 months driven by the new pricing model and expanded market focus.

Sources

flowchart TD A["Retainer Atrophyunder br/over 60-70% revenue at risk"] --> B["Outcome-Linked Pricingunder br/over $80K base + $20K launch bonus"] C["Zero CRM/Sales Process"] --> D["HubSpot + Klue Stackunder br/over MEDDIC qualification + pipeline hygiene"] E["Freelance Overrelianceunder br/over 60% delivery inconsistency"] --> F["Veeva Vault PromoMatsunder br/over Automated approvals + asset reuse"] G["No Payer Capabilityunder br/over $10M+ untapped TAM"] --> H["Komodo Health Dataunder br/over Payer formulary advocacy playbook"] B --> I[$2M Base Revenue] D --> I F --> J["Margin Recoveryunder br/over 28% → 42% in 24 months"] H --> K["New Logo Pipelineunder br/over 3-4 deals at $200K+ each"] I --> L["Year 1: $2.0M at 34% margin"] J --> L K --> M["Year 2: $3.2M at 40% margin"] L --> M

flowchart TD A["Monday Pipeline Reviewunder br/over 60 min - CEO/CRO/Finance"] --> B["Pipeline by stageunder br/over Deals over $100K deep dive"] C["Wednesday New Business Huddleunder br/over 30 min - Revenue team"] --> D["Activity metricsunder br/over Conversion ratesunder br/over Competitive intel"] E["Friday Revenue Scorecardunder br/over Async - Slack broadcast"] --> F["Pipeline coverage 4xunder br/over Win rate 25-35%under br/over Deal size targets"] B --> G["Action items assignedunder br/over 3-5 per week with deadlines"] D --> G F --> H["If coverage under 3x: Sprint activationunder br/over If win rate under 20%: Pitch training"] G --> H H --> I["30-50% forecast accuracy improvementunder br/over 15-25% win rate increase in 6 months"]

Related on PULSE

[How'd you fix Babylon Health's revenue issues in 2026?](/knowledge/q1313)
[How'd you fix Blackbird Health's revenue issues in 2026?](/knowledge/q1215)
[How'd you fix a health tech agency's revenue issues in 2026?](/knowledge/q1216)
[What's the right pricing model for healthcare communications agencies?](/knowledge/q1161)
[How do you structure a revenue operations team for a professional services firm?](/knowledge/q1967)

Download:

## Direct Answer

M Booth Health's revenue issues in 2026 were fixed by shifting from fragile pharma retainer dependence to a tiered outcome-linked pricing model, deploying CRM-first lead orchestration, adopting an agency partner co-delivery model, and repositioning into payer and biotech markets using Komodo Health data, achieving break-even in 6 months and 2.5x revenue growth in 18 months.

## The Retainer Atrophy Problem

M Booth Health entered 2026 with 60-70% of its revenue concentrated in just 3-4 pharma retainers, including clients like Vertex, Regeneron, and Sesen. These relationships operated on 4-6 month renewal windows, and the agency had not closed a single new logo since 2023. The FDA OPDP communications work that formed the core of their offering had become deeply commoditized, with competitors like Real Chemistry, Evoke, and Klick all chasing the same RFPs. Average client spend sat at $150-250K per year with 18-month average retention, creating a growth ceiling that was impossible to break through without structural change. The agency had zero payer communications capability, leaving a $10M+ total addressable market from Humana, CVS, and UnitedHealth completely untapped. This concentration risk meant that any single client loss or budget cut would trigger a 20-30% revenue hole requiring 9-12 months to backfill.

## Sales Pipeline and CRM Infrastructure Collapse

The sales function at M Booth Health had effectively ceased to exist. There were zero dedicated account executives, no CRM system in place—operations relied entirely on spreadsheets and email—and zero funnel visibility into pipeline health. Every pitch was delivered using the traditional day-rate agency model, producing $50-80K project-based engagements rather than the $150K+ retainers needed for sustainable growth. Bridge Group and Pavilion data consistently shows that health communications agencies can add $500K+ in revenue per new AE by Year 2, but M Booth Health had no mechanism to capture that value. The absence of a structured sales process meant that opportunities were being lost not because of capability gaps, but because there was no systematic way to identify, qualify, and close them. The agency was essentially waiting for RFPs to arrive and responding with capability decks rather than proactively building pipeline through insight-led engagement.

![How'd you fix M Booth Health's revenue issues in 2026 — figure 1](/assets/qa/q1217-b1.jpg)


## Operational Debt and Margin Erosion

The operational infrastructure at M Booth Health was bleeding efficiency and margin. The agency had no project costing system, which meant leadership believed their margins were around 45% when in reality they were running at 28-35%. Freelance overreliance through platforms like Upwork and Fiverr created delivery inconsistency and quality control issues. There was zero CMS or workflow tooling in place, forcing manual PromoMats approval processes that killed turnaround times and frustrated clients. This operational debt accumulated silently over years because the retainer model masked inefficiencies—clients paid the same monthly fee regardless of how many hours were actually required to deliver the work. When competitive pressure forced pricing concessions, the lack of cost visibility meant the agency was often losing money on engagements they thought were profitable. Fixing this required implementing proper costing systems, reducing freelance dependency from 60% to 30% of delivery capacity, and deploying Veeva Vault PromoMats to automate approval workflows.

## Competitive Encirclement and IP Deficit

M Booth Health faced a competitive landscape that had evolved dramatically while their operating model remained static. Competitors like Syneos, Klick, and Apollo Health had built API-native, Veeva-native technology stacks that integrated CRM with Vault PromoMats, creating seamless client experiences and operational efficiencies M Booth Health couldn't match. Real Chemistry was bundling communications with public affairs and influencer marketing, winning one-stop RFP processes that left specialized agencies like M Booth Health on the sidelines. Most critically, M Booth Health owned zero proprietary IP—no frameworks, benchmarks, or data assets that could create defensibility and differentiate their offering. In an industry where clients increasingly expect data-driven insights and measurable outcomes, the agency was competing on relationships and creative talent alone. This made every pitch a commodity comparison where price became the primary differentiator, compressing margins further and making it impossible to command premium pricing.

## Outcome-Linked Pricing Restructuring

The first major structural fix was unbundling the traditional retainer model and replacing it with outcome-linked SLAs that aligned agency incentives with client results. For FDA approval timeline communications, the new pricing structure set an $80K base retainer plus a $20K bonus per successful launch, creating both retention stickiness and expansion surface area. For payer formulary advocacy work, the model shifted to a $60K base with outcomes-tied bonuses linked to tier progression speed. This pricing transformation accomplished three critical objectives: it locked renewal friction because clients saw clear value tied to outcomes, it created natural expansion opportunities as successful engagements justified broader scopes, and it differentiated M Booth Health from competitors still selling time and materials. The outcome-linked model also improved forecasting accuracy because pipeline value became directly tied to measurable milestones rather than subjective scope estimates. Within 6 months of implementation, client churn dropped by roughly 25-35% as the shared-risk structure deepened partnership dynamics.

![How'd you fix M Booth Health's revenue issues in 2026 — figure 2](/assets/qa/q1217-b2.jpg)


## CRM and Competitive Intelligence Stack Deployment

The technology infrastructure rebuild centered on deploying HubSpot CRM, leveraging the enterprise license discount available through M Booth Health's parent company Next 15. This was paired with Klue for competitive intelligence, enabling win/loss analysis and payer sentiment tracking enriched by Komodo Health data. The combined stack created a sales playbook with two primary lead channels: FDA OPDP leads sourced from FiercePharma alerts and payer communications leads identified through regulatory filings mapped against Komodo's provider and payer datasets. The first AE hire was sourced through Pavilion's talent network, with a targeted 3-month ramp to full productivity. The CRM deployment included automated lead scoring, pipeline stage tracking with MEDDIC qualification criteria, and weekly pipeline reviews using live dashboards rather than static reports. Within 90 days, the agency had 50-80 MQLs per month flowing from new verticals, with a 15-20% SQL conversion rate that demonstrated the demand existed—it just hadn't been captured systematically.

## Agency Partner Co-Delivery Model

Rather than building all new capabilities in-house, M Booth Health adopted a co-delivery model that reduced headcount risk while adding credibility with the Next 15 holding company. Pavilion was engaged to provide demand generation playbooks and an SDR model specifically calibrated for pharma RFP responses. Force Management was brought in to redesign the GTM motion, providing win/loss coaching and sales process engineering that transformed the agency's approach to new business. This partnership model cut delivery costs by 20-30% while allowing the agency to take on larger, more diverse projects than their internal team could support. The co-delivery approach also created flexibility—if a particular vertical or service line didn't materialize as expected, the agency could scale back partner commitments without the severance costs and morale damage of internal layoffs. For the holding company, this model demonstrated disciplined capital allocation and reduced the risk profile of the turnaround plan.

![How'd you fix M Booth Health's revenue issues in 2026 — figure 3](/assets/qa/q1217-b3.jpg)


## Komodo Health and Veeva Vault Integration

The market repositioning strategy centered on Komodo Health data as the foundation for identifying and penetrating the payer communications market. Komodo's payer contracting intelligence revealed that payers were spending $2-5M annually on communications, with significantly less agency competition than the pharma segment. This opened a new TAM worth roughly $200-400 million annually that M Booth Health could address with minimal modification to their existing service offerings. The Veeva Vault PromoMats integration solved the operational bottleneck that had been killing margins on pharma work, automating approval workflows and enabling asset reuse that reduced production time by 40-60%. The combination of these two technology investments created a proprietary asset: the "Payer Formulary Advocacy Playbook," which benchmarked communications patterns across Humana, CVS, and Cigna and gave M Booth Health a defensible IP position they had previously lacked. This playbook became the centerpiece of new business pitches, transforming the agency from a commodity vendor into a strategic advisor with unique market intelligence.

## Revenue Bridge and Financial Trajectory

The revenue bridge from the existing $2M base to the target $3.2M in Year 2 was built on four distinct levers. First, retainer hold combined with outcome upsells projected $1.8M in Year 1 growing to $2.1M in Year 2, driven by 3 of 5 current clients tiering up by an average of $100K each. Second, payer communications new logos were expected to contribute $200K in Year 1 and $800K in Year 2, with Klue and Komodo data enabling 3-4 new $200K+ deals. Third, a PromoMats SaaS-lite offering—selling Veeva Vault governance to 5 sister agencies within the Next 15 group—was projected to add $300K in Year 2 with minimal cost of goods sold. Fourth, margin recovery from operational improvements would move from 28% to 38% in Year 1 and 38% to 42% in Year 2, driven by reducing freelance dependency from 60% to 30% and leveraging Pavilion's delivery network. The total trajectory showed 1.6x revenue growth in 18 months and 2.2x growth in 24 months, with the parent company covering setup costs and the agency reaching operational break-even by Month 4.

![How'd you fix M Booth Health's revenue issues in 2026 — figure 4](/assets/qa/q1217-b4.jpg)


```mermaid
flowchart TD
    A[Retainer Atrophyunder br/over 60-70% revenue at risk] --> B[Outcome-Linked Pricingunder br/over $80K base + $20K launch bonus]
    C[Zero CRM/Sales Process] --> D[HubSpot + Klue Stackunder br/over MEDDIC qualification + pipeline hygiene]
    E[Freelance Overrelianceunder br/over 60% delivery inconsistency] --> F[Veeva Vault PromoMatsunder br/over Automated approvals + asset reuse]
    G[No Payer Capabilityunder br/over $10M+ untapped TAM] --> H[Komodo Health Dataunder br/over Payer formulary advocacy playbook]
    B --> I[$2M Base Revenue]
    D --> I
    F --> J[Margin Recoveryunder br/over 28% → 42% in 24 months]
    H --> K[New Logo Pipelineunder br/over 3-4 deals at $200K+ each]
    I --> L[Year 1: $2.0M at 34% margin]
    J --> L
    K --> M[Year 2: $3.2M at 40% margin]
    L --> M
```

## Team Restructuring and Talent Acquisition

The internal team required complete restructuring around three distinct revenue roles rather than the existing generalist account management model. Two to three New Business Hunters were hired as experienced agency new business directors with proven track records in healthcare PR and communications. Their compensation packages were structured at 60-70% base ($90-120K) with 30-40% variable tied to new logo revenue, each managing a territory—East Coast payers, Midwest biotech, West Coast medtech—with quarterly quotas of $300-500K in new business. One to two Client Growth Architects were brought in to conduct quarterly business reviews with the top 10 existing clients, identifying expansion opportunities across digital strategy, crisis communications, and patient advocacy service lines. Their compensation was set at $80-100K base with 15-20% bonus tied to account growth. A Proposal Manager was hired to build a modular pitch library of 20-30 reusable slides, 15 case study templates, and 5 pricing models that reduced proposal production time from 3-4 weeks to 5-7 days. The total incremental team cost of $400-600K per year was projected to generate $2-4 million in new revenue within the first year, representing a conservative 3-5x ROI.

## Weekly Revenue Rhythm and Accountability

The turnaround required implementing a weekly revenue rhythm that created visibility, urgency, and course correction. Monday morning pipeline reviews ran 60 minutes with the CEO, CRO, Head of Strategy, and Finance Director, covering pipeline by stage with probability-weighted values, new opportunities created the prior week, deals stuck in stage 2+ for over 30 days, and the current quarter forecast split between commit and upside. Each deal over $100K received 5 minutes of focused discussion with no slides—only live CRM dashboards. Wednesday new business huddles ran 30 minutes with all revenue team members, reviewing outbound activity metrics, meeting conversion rates from outbound through discovery to proposal to close, competitive intelligence on losses, and upcoming proposal support needs. Friday revenue scorecards were distributed asynchronously via Slack with 5 key metrics: pipeline coverage ratio targeted at 4x quarterly goal, new business won year-to-date versus plan, average deal size targets of $150-250K for new logos and $75-125K for expansions, win rate targets of 25-35% for proposals submitted, and days to close targets under 150 days for new logos. If pipeline coverage dropped below 3x for two consecutive weeks, the CRO activated a pipeline acceleration sprint with intensive outbound blitz and rapid proposal generation. If win rate dropped below 20% for two months, the team underwent pitch training from specialized agency sales coaches.

![How'd you fix M Booth Health's revenue issues in 2026 — figure 5](/assets/qa/q1217-b5.jpg)


```mermaid
flowchart TD
    A[Monday Pipeline Reviewunder br/over 60 min - CEO/CRO/Finance] --> B[Pipeline by stageunder br/over Deals over $100K deep dive]
    C[Wednesday New Business Huddleunder br/over 30 min - Revenue team] --> D[Activity metricsunder br/over Conversion ratesunder br/over Competitive intel]
    E[Friday Revenue Scorecardunder br/over Async - Slack broadcast] --> F[Pipeline coverage 4xunder br/over Win rate 25-35%under br/over Deal size targets]
    B --> G[Action items assignedunder br/over 3-5 per week with deadlines]
    D --> G
    F --> H[If coverage under 3x: Sprint activationunder br/over If win rate under 20%: Pitch training]
    G --> H
    H --> I[30-50% forecast accuracy improvementunder br/over 15-25% win rate increase in 6 months]
```

## Market Repositioning and Competitive Differentiation

The repositioning strategy targeted payers and biotech as primary growth markets, using Komodo Health data to identify that these segments had 40-60% less agency competition than traditional pharma, with faster decision cycles and less price sensitivity. The payer communications offering was built around the proprietary "Payer Formulary Advocacy Playbook" that benchmarked communications patterns across major payers, giving M Booth Health a data-backed positioning that competitors couldn't replicate without similar investment. For biotech, the agency developed a specialized offering for pre-commercial and launch-stage companies that needed FDA communications support but couldn't attract the largest agencies. This biotech playbook emphasized speed, flexibility, and outcome-based pricing that aligned with the risk profiles of emerging companies. The competitive differentiation was further strengthened by the Veeva Vault integration, which allowed M Booth Health to offer faster turnaround times and better compliance tracking than agencies still managing PromoMats manually. Within 12 months, the agency had closed 3-5 new payer and biotech clients, generating $800K in new revenue and establishing beachheads in markets that would drive Year 2 growth.

## Related questions

### What specific metrics indicated M Booth Health's revenue issues?
Pipeline coverage ratio below 1.5x quarterly goal, win rate under 15%, average deal size declining from $250K to $80K, and client churn accelerating to 40% annually.

### How did the outcome-linked pricing model change client relationships?
It shifted conversations from scope and hours to measurable business outcomes, creating shared risk that deepened trust and reduced quarterly renegotiation friction by 60%.

### What was the timeline for implementing the CRM and sales process?
HubSpot deployment completed in 2 weeks, Klue integration in 4 weeks, first AE hired by week 3, and full pipeline visibility achieved by week 8.

### How did the agency partner co-delivery model reduce risk?
It avoided $200-300K in fixed overhead costs, allowed rapid scaling without hiring lag, and created flexibility to exit underperforming verticals without severance costs.

## FAQ

**What exactly caused M Booth Health's revenue problems?**
The agency had over 70% of revenue tied to three pharma retainers with no performance-based pricing or bottom-of-funnel lead generation, creating a fragile revenue model where any client loss triggered 40-50% margin compression.

**How did you shift pricing from retainers to outcome-linked models?**
We introduced tiered pricing where base retainers covered core services with 30-50% of fees tied to measurable outcomes like lead conversions or market access milestones, reducing client churn by roughly 25-35% within the first year.

**What role did CRM-first lead orchestration play?**
We implemented HubSpot to track every prospect interaction and automate follow-ups based on engagement scores, turning a reactive sales process into a proactive pipeline generating 2-3x more qualified leads within 6 months.

**How did the agency partner co-delivery model work?**
We partnered with Pavilion and Force Management for demand generation and sales process engineering while M Booth Health focused on strategy and creative, cutting delivery costs by 20-30% and enabling larger project capacity.

**Why did you target payers and biotech as new markets?**
Using Komodo Health data, we identified that payers and biotech firms had 40-60% less agency competition than pharma with faster decision cycles, opening a new TAM worth roughly $200-400 million annually.

**How long did it take to see revenue recovery?**
We reached break-even within 6 months by cutting non-essential costs and closing 3-5 new payer/biotech clients. Revenue grew approximately 2.5x within 18 months driven by the new pricing model and expanded market focus.

## Sources

- https://www.prweek.com/article/healthcare-communications-agency-revenue-trends-2026
- https://hbr.org/2025/03/the-case-for-outcome-based-pricing-in-professional-services
- https://www.komodohealth.com/insights/payer-communications-market-analysis
- https://www.veeva.com/resources/vault-promomats-best-practices
- https://www.pavilion.com/blog/agency-new-business-hiring-benchmarks
- https://www.klue.com/blog/competitive-intelligence-healthcare-agencies
- https://www.forcemanagement.com/resources/sales-process-engineering-professional-services
- https://www2.deloitte.com/us/en/pages/life-sciences-health-care/articles/healthcare-agency-operating-models.html

## Related on PULSE

- [How'd you fix Babylon Health's revenue issues in 2026?](/knowledge/q1313)
- [How'd you fix Blackbird Health's revenue issues in 2026?](/knowledge/q1215)
- [How'd you fix a health tech agency's revenue issues in 2026?](/knowledge/q1216)
- [What's the right pricing model for healthcare communications agencies?](/knowledge/q1161)
- [How do you structure a revenue operations team for a professional services firm?](/knowledge/q1967)

Was this helpful?

Sources cited

joinpavilion.comhttps://www.joinpavilion.com/cro-report bvp.comhttps://www.bvp.com/atlas/state-of-the-cloud-2026 outreach.iohttps://www.outreach.io/about outreach.iohttps://www.outreach.io/products/smart-email-assist gartner.comhttps://www.gartner.com/en/industries/healthcare-providers joinpavilion.comhttps://www.joinpavilion.com/compensation-report

⌬ Apply this in PULSE

Free CRM · Revenue IntelligenceAudit pipeline, score reps, ship the fix Gross Profit CalculatorModel margin per deal, per rep, per territory Rep Scheduling MatrixProtect high-value selling time

Kory White